<DOC>
	<DOC>NCT00505102</DOC>
	<brief_summary>The purpose of this study is to verify whether the reduction of cyclosporine dosages associated with Everolimus administration may improve renal function as compared to patients maintained on standard immunosuppressive therapy</brief_summary>
	<brief_title>Safe Renal Function In Long Term Heart Transplanted Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Heart Transplant patients with more than 1 year of followup Creatinine lower than 3.5 mg/dl GFR Higher than 20 ml/min (calculated with CockcroftGault formula) Cyclosporine in maintenance immunosuppressive therapy Patient must be able to sign an approve informed consent Prior History of acute rejection within the last 3 months Females of childbearing age may be included if pregnancy is excluded and acceptable contraception measures are used Patients who are recipients of multiple organ transplants Prior or current use of sirolimus or everolimus History of acute rejection within the last 6 months Coronary Artery Bypass Surgery or other cardiac surgery in the past 3 months Patient not able to attend all followup evaluations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Kidney Diseases</keyword>
	<keyword>Heart Transplantation</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Cyclosporine Toxicity</keyword>
</DOC>